SRTD Biotech raises €31.5 million seed round for precision mRNA therapeutics
SRTD Biotech has completed a €31.5 million seed financing led by Mérieux Equity Partners and co-led by NRW.BANK and Boehringer Ingelheim Venture Fund. Lilly Ventures, HTGF and Anobis Asset also participated, with the proceeds funding preclinical development of targeted RNA therapies.
- Raised
- €31.5 million
- Round
- seed
- Investors
- 6
- Investors
- Mérieux Equity PartnersNRW.BANKBoehringer Ingelheim Venture FundLilly VenturesHTGFAnobis Asset
- Target market
- Oncology, autoimmune and fibrosis indications
- Use of funds
- Funding preclinical development of targeted RNA therapies across oncology, autoimmune and fibrosis indications towards IND
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about SRTD Biotech?
SRTD Biotech has completed a €31.5 million seed financing led by Mérieux Equity Partners and co-led by NRW.BANK and Boehringer Ingelheim Venture Fund. Lilly Ventures, HTGF and Anobis Asset also participated, with the proceeds funding preclinical development of targeted RNA therapies.
What does SRTD Biotech do?
SRTD Biotech was co-founded by Dr. Bernd Hoffmann in 2019 and is headquartered in Jülich, Germany.
How much did SRTD Biotech raise?
SRTD Biotech raised €31.5 million in its seed.
Who invested in SRTD Biotech?
Investors named in this seed include Mérieux Equity Partners, NRW.BANK, Boehringer Ingelheim Venture Fund, Lilly Ventures, HTGF and Anobis Asset.
How will SRTD Biotech use the funding?
SRTD Biotech plans to use the money for funding preclinical development of targeted RNA therapies across oncology, autoimmune and fibrosis indications towards IND.
Where is SRTD Biotech based?
SRTD Biotech is based in Germany.
Who are the key people at SRTD Biotech?
Key people named in this report: Dr. Bernd Hoffmann (Chief Scientific Officer and Founder), Matthias Alder (CEO) and Dr. Heinz Koeppl (CTO).